Project Grant R44HL184837
Award Date 9/1/26
Completion Date 2/28/27
Dollars Obligated $300K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded $799,998 to The Trustees of the University of Pennsylvania on August 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiotropic solid lipid nanoparticles (LNPs) as a drug and biologic delivery platform for cardiac therapeutics. The research focuses on engineering and understanding heart-targeting LNPs that accumulate in cardiac tissue at significantly higher concentrations than existing drug delivery...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $1,540,883 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a new lipid-lowering and anti-inflammatory siRNA therapy for atherosclerosis treatment. The project targets epsin endocytic adaptor proteins through dual-tissue siRNA lipid nanoparticles engineered to simultaneously silence epsins in the liver and atherosclerotic plaques. The approach combines...
- The National Institute of Biomedical Imaging and Bioengineering awarded $645,265 to The Trustees of The University of Pennsylvania on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop DNA-loaded lipid nanoparticles (DNA-LNPs) for treating chronic diseases including atherosclerosis and emphysema. The research addresses toxicity barriers that have prevented DNA-LNP development for two decades. Prior...
- The National Heart, Lung, and Blood Institute awarded Pop Biotechnologies Inc. $309,794 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, for a Phase I Small Business Innovation Research project to develop a liposome-displayed apolipoprotein B fragment vaccine candidate for active immunotherapy against atherosclerosis. Pop Biotechnologies will advance a P210 peptide vaccine by combining it with the company's spontaneous nanoliposome antigen particle (SNAP)...
- The National Heart, Lung, and Blood Institute awarded Duke University $814,943 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop non-viral gene therapy approaches for cardiac regeneration following myocardial injury. Duke University will develop cardiac-targeted lipid nanoparticles for in vivo transfection of cardiomyocytes and adapt a cell-state sensing platform (CELLREADR) to deliver therapeutic transgenes with cell-type precision to injured...
- The National Heart, Lung, and Blood Institute awarded The University of North Texas Health Science Center at Fort Worth $426,550 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a bioengineering modular gene delivery system for lung-targeted transgene expression. The project addresses systemic gene therapy for monogenic lung diseases including cystic fibrosis, alpha-1-antitrypsin deficiency, and pulmonary arterial hypertension. The recipient...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Brigham & Womens Hospital Inc. $1,242,222 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate non-coding RNAs as therapeutic targets in chronic limb-threatening ischemia. The funded research addresses the pathophysiology of chronic limb-threatening ischemia (CLTI), a leading cause of amputation in adults affecting over 200 million people globally. The project will...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $632,081 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop conformation-sensitive platelet-hitchhiking lipid nanoparticles for targeted delivery of mRNA and small interfering RNA to infarcted heart tissue following myocardial infarction. The project addresses therapeutic limitations in post-infarction recovery by engineering lipid nanoparticles to...
- The National Heart, Lung, and Blood Institute awarded $1,137,435 to the University of Pennsylvania on March 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance therapeutic gene-editing approaches for cardiovascular and inherited disease. The recipient is developing and translating gene-editing therapies across three therapeutic domains. The first targets liver-centered, multiplex editing to prevent atherosclerotic cardiovascular disease through tunable...
- The National Heart, Lung, and Blood Institute awarded Beth Israel Deaconess Medical Center, Inc. $852,908 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to design and optimize elastin-like polypeptide (ELP) nanoparticles for pulmonary gene therapy of cystic fibrosis. The funded work develops fourth-generation ELP nanoparticles engineered to self-assemble into pH-responsive micellar nanoparticles for cytosolic delivery of mRNA, pDNA, proteins, and RNPs to...